There are also limitations: Although GFAP is a robust glioma marker, it does not label all glioma subpopulations (e.g., GFAP-negative tumor cells), and future work could incorporate additional markers (e.g., Sox2, Olig2). This evidence concerns the gene SOX2 and neoplasm.